Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
The first FDA-cleared device that supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our five FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without additional equipment, procedures or radiation dose.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
MIAMISBURG, Ohio (December 2, 2024) – Technology that suppresses vessels in chest CTs reduced resident and attending radiologists’ reading times by 6.9 and 1.4 minutes, respectively, in a study presented at the Radiological Society of North America (RSNA) annual meeting. The study used ClearRead CT Vessel Suppression by Riverain Technologies and demonstrated faster chest CT reading times for identifying pulmonary nodules.
“This study highlights the benefits of ClearRead CT in terms of increased reading efficiency when radiologists have an unimpaired view of a chest CT,” said Steve Worrell, CEO, Riverain Technologies. “Our AI-powered ClearRead technology provides a clear view of the lungs, so radiologists can identify actionable pulmonary nodules faster and sooner.”
The study, led by radiology researchers at the University of Washington School of Medicine, found the average time from study opening to closing decreased significantly, from 19.1 minutes to 12.2 minutes when using vessel suppression technology and from 6.6 minutes to 5.2 minutes for radiology attendings in a primarily oncology patient population.
“The detection of pulmonary nodules on CT chest scans is a critical yet time-consuming component of quality patient care. Using real-world radiology workflows, we found that Riverain’s vessel suppression technology reduced reading times for both residents and attending physicians,” said Kevin Chorath, MD, a resident in the UW School of Medicine’s Department of Radiology.
Powered by advanced machine learning and modeling, Riverain’s patented, FDA-cleared ClearRead software tools are deployed across academic medical centers, veterans’ hospitals, and radiology groups.
Disclaimer: The study was done independently by the University of Washington and does not imply an endorsement or promotion of Riverain Technologies’ products. No compensation was received by UW Medicine researchers for the study or its presentation at RSNA.
About Riverain Technologies
Riverain Technologies is dedicated to transforming the field of radiology by addressing and eliminating delayed cardiothoracic diagnoses. As relentless innovators, Riverain empowers healthcare providers by streamlining diagnostic workflows, enhancing detection accuracy, and ultimately improving patient outcomes. With a steadfast commitment to advancing cardiothoracic care, Riverain Technologies is shaping the future of diagnostic excellence. For more information: https://www.riveraintech.com/
Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
